Clinical utility of morphology, immunohistochemistry, flow cytometry, and FISH analysis in monitoring of plasma cell neoplasms in the bone marrow

详细信息    查看全文

• 作者：Oluyomi E. Ajise ; Mikhail Roshal ; Lu Wang…
• 关键词：Bone marrow ; Plasma cell myeloma ; Flow cytometry ; Immunohistochemistry ; FISH
• 刊名：Journal of Hematopathology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：9
• 期：1
• 页码：9-18
• 全文大小：1,410 KB
• 参考文献：1.Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111(6):2962–2972. doi:10.​1182/​blood-2007-10-078022 PubMedCentral CrossRef PubMed
  2.Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA: Cancer J Clin 58(2):71–96. doi:10.​3322/​CA.​2007.​0010
  3.Zhan F, Sawyer J, Tricot G (2006) The role of cytogenetics in myeloma. Leukemia 20(9):1484–1486. doi:10.​1038/​sj.​leu.​2404330 CrossRef PubMed
  4.Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101(11):4569–4575. doi:10.​1182/​blood-2002-10-3017 CrossRef PubMed
  5.Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23(12):2210–2221. doi:10.​1038/​leu.​2009.​174 PubMedCentral CrossRef PubMed
  6.Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel J, Crowley J, Avet-Loiseau H (2011) Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 117(18):4696–4700. doi:10.​1182/​blood-2010-10-300970 PubMedCentral CrossRef PubMed
  7.Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working G (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467–1473. doi:10.​1038/​sj.​leu.​2404284 CrossRef PubMed
  8.Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J, International Myeloma Workshop Consensus P (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117(18):4691–4695. doi:10.​1182/​blood-2010-10-299487 PubMedCentral CrossRef PubMed
  9.Ng AP, Wei A, Bhurani D, Chapple P, Feleppa F, Juneja S (2006) The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica 91(7):972–975PubMed
  10.Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS (2001) Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 14(10):1052–1058. doi:10.​1038/​modpathol.​3880435 CrossRef PubMed
  11.Chilosi M, Adami F, Lestani M, Montagna L, Cimarosto L, Semenzato G, Pizzolo G, Menestrina F (1999) CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol 12(12):1101–1106PubMed
  12.Natkunam Y, Warnke RA, Montgomery K, Falini B, van De Rijn M (2001) Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 14(7):686–694. doi:10.​1038/​modpathol.​3880373 CrossRef PubMed
  13.Turley H, Jones M, Erber W, Mayne K, de Waele M, Gatter K (1994) VS38: a new monoclonal antibody for detecting plasma cell differentiation in routine sections. J Clin Pathol 47(5):418–422PubMedCentral CrossRef PubMed
  14.Al-Quran SZ, Yang L, Magill JM, Braylan RC, Douglas-Nikitin VK (2007) Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry. Hum Pathol 38(12):1779–1787. doi:10.​1016/​j.​humpath.​2007.​04.​010 PubMedCentral CrossRef PubMed
  15.Craig FE, Foon KA (2008) Flow cytometric immunophenotyping for hematologic neoplasms. Blood 111(8):3941–3967. doi:10.​1182/​blood-2007-11-120535 CrossRef PubMed
  16.Smock KJ, Perkins SL, Bahler DW (2007) Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment. Arch Pathol Lab Med 131(6):951–955. doi:10.​1043/​1543-2165(2007)131[951:​qopcib]2.​0.​co;2 PubMed
  17.Nadav L, Katz BZ, Baron S, Yossipov L, Polliack A, Deutsch V, Geiger B, Naparstek E (2006) Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration. Br J Haematol 133(5):530–532. doi:10.​1111/​j.​1365-2141.​2006.​06068.​x CrossRef PubMed
  18.Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omede P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE (2008) Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 93(3):431–438. doi:10.​3324/​haematol.​11080 CrossRef PubMed
  19.San Miguel JF, Gutierrez NC, Mateo G, Orfao A (2006) Conventional diagnostics in multiple myeloma. Eur J Cancer 42(11):1510–1519. doi:10.​1016/​j.​ejca.​2005.​11.​039 CrossRef PubMed
  20.Lin P, Owens R, Tricot G, Wilson CS (2004) Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 121(4):482–488. doi:10.​1309/​74r4-tb90-buwh-27jx CrossRef PubMed
  21.De Vis J, Renmans W, Segers E, Jochmans K, De Waele M (1991) Flow cytometric immunophenotyping of leukemia cells in clotted blood and bone marrow. J Immunol Methods 137(2):193–197CrossRef PubMed
  22.Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, Gutierrez NC, Garcia de Coca A, de Las HN, Mateos MV, Lopez-Berges MC, Garcia-Boyero R, Galende J, Hernandez J, Palomera L, Carrera D, Martinez R, de la Rubia J, Martin A, Blade J, Lahuerta JJ, Orfao A, San Miguel JF (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112(10):4017–4023. doi:10.​1182/​blood-2008-05-159624 PubMedCentral CrossRef PubMed
  
• 作者单位：Oluyomi E. Ajise (1) (2)
  Mikhail Roshal (1)
  Lu Wang (1)
  Goutamie N. Sukhram (1)
  Katherine M. Smith (1)
  Peter Maslak (1)
  Ahmet Dogan (1)
  
  1. Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
  2. Department of Pathology, McGill University, Montreal, Quebec, H3A 2B4, Canada
  
• 刊物主题：Pathology; Hematology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1865-5785

文摘

In this study, we examined clinical utility of morphology, immunohistochemistry (IHC), flow cytometric immunophenotyping (FC), and multiple myeloma (MM)-specific fluorescence in situ hybridization (FISH) in evaluation of disease burden in bone marrow (BM) of plasma cell neoplasms (PCNs). Of the 100 consecutive BM samples, 81 demonstrated PCN. CD138 IHC was the most sensitive technique to assess PCN burden compared to aspirate count or flow cytometry with mean values of 30 % (range 3–100), 19 (1–78), and 2.1 (0.01–33.2), respectively. CD138 IHC correlated well with the aspirate count (r 2 = 0.5) but poorly with FC (r 2 = 0.1). FC demonstrated the highest sensitivity in assessment of clonality 96 % (79/82), while morphology and IHC was positive in 84 % (71/82), FISH in 79 % (59/75) cases. Our results show that CD138 IHC is the most sensitive method for assessment of BM PCN burden whereas FC is the most sensitive method to establish the clonal nature of the PCN.